Condition: Anatomic Stage II Breast Cancer AJCC v8 · Anatomic Stage III Breast Cancer AJCC v8 · HER2-Negative Breast Carcinoma · Sponsor: National Cancer Institute (NCI)
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham Cancer Center | Birmingham, Alabama, United States | Recruiting |
| Katmai Oncology Group | Anchorage, Alaska, United States | Recruiting |
| University of Arizona Cancer Center-Orange Grove Campus | Tucson, Arizona, United States | Recruiting |
| Banner University Medical Center - Tucson | Tucson, Arizona, United States | Recruiting |
| University of Arizona Cancer Center-North Campus | Tucson, Arizona, United States | Recruiting |
| Mercy Hospital Fort Smith | Fort Smith, Arkansas, United States | Recruiting |
| NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro | Jonesboro, Arkansas, United States | Recruiting |
| University of Arkansas for Medical Sciences | Little Rock, Arkansas, United States | Recruiting |
| Sutter Auburn Faith Hospital | Auburn, California, United States | Recruiting |
| AIS Cancer Center at San Joaquin Community Hospital | Bakersfield, California, United States | Recruiting |
| Alta Bates Summit Medical Center-Herrick Campus | Berkeley, California, United States | Recruiting |
| Tower Cancer Research Foundation | Beverly Hills, California, United States | Recruiting |
+ 531 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06058377